The U106 study (NCT04042701), a phase IB study, tested a combination of T-DXd and pembrolizumab in ICI-treatment-naïve HER2-overexpressing (n = 22) or ERBB2-mutated (n = 33) patients with NSCLC [88]. Here, ERBB2 is linked to non-small cell lung carcinoma.